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Abstract 
 
Background: Meta-analyses of trials comparing thrombolysis and primary 
angioplasty following an acute myocardial infarction (AMI) have shown benefits 
for angioplasty.  Choice of therapy needs to consider the relationship between 
this benefit and any time delay in initiating angioplasty.   
 
Objective: To extend earlier meta-analyses of these alternative forms of 
reperfusion by considering both 1- and 6-month outcome data.  To use 
Bayesian statistical methods to quantify more fully the uncertainty associated 
with the estimated relationships.  
 
Methods: A systematic review and meta-analysis published in 2003 was 
updated with recently published trials.  Data on key clinical outcomes and the 
difference between time-to-balloon and time-to-needle were independently 
extracted by two researchers.  Bayesian statistical methods were used to 
synthesise evidence despite differences between trials in follow-up times and 
reported outcomes.  Outcomes are presented as absolute probabilities of 
specific events and odds ratios (with 95% credible intervals (CrI)) as a function 
of the additional time-delay associated with angioplasty.   
 
Results: A total of 22 studies were included in the meta-analysis, with 3,760 
and 3,758 patients randomised to primary angioplasty and thrombolysis, 
respectively.  The mean angioplasty-related time delay (over and above time to 
thrombolysis) was 54.3 minutes (S.E. 2.2).  For this average delay, the mean 
event probabilities are lower for primary angioplasty for all outcomes. Mortality 
within 1 month is 4.5% following angioplasty and 6.4% after thrombolysis (odds 
ratio of 0.68 (95% CrI 0.46, 1.01)).  For non-fatal re-infarction, the odds ratio is 
0.32 (95% CrI 0.20, 0.51); and for non-fatal stroke it is 0.24 (95% CrI 0.11, 
0.50).  For all outcomes, the benefit of angioplasty decreases with longer delay 
from initiation.     
 
Conclusions: The benefit of primary angioplasty, over thrombolysis, depends 
on the former’s additional time delay.   For delays between 30 and 90 minutes, 
angioplasty is superior, on average, for 1-month fatal and non-fatal outcomes. 
Thrombolysis may be the preferred option in terms of 6-month mortality only for 
delays at around 90 minutes and beyond but there is considerable uncertainty 
for longer time delays. 
 
 
Keywords: Acute myocardial infarction, primary coronary angioplasty, 
thrombolytics, meta-regression. 
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INTRODUCTION 
In the UK, at least 87,000 individuals under the age of 75 years suffer an acute 
myocardial infarction (AMI) each year.1 The relationship between normal 
coronary artery blood flow and mortality after MI is well documented,2 so early 
restoration of normal myocardial blood flow is a prime therapeutic goal for the 
management of MI. Pharmacological treatment with thrombolytic therapy and 
primary angioplasty are two different modes of reperfusion therapy for ST 
elevation AMI (STEMI).  
 
Meta-analyses of the various randomised trials comparing thrombolysis and 
primary angioplasty have shown substantial benefits from angioplasty in terms 
of mortality, non-fatal re-infarction and stroke;2-5 and they have also shown that 
angioplasty has lower recurrence rates and less residual stenosis.6,7 Despite 
the apparent clinical superiority of primary angioplasty, thrombolytic treatment is 
the default treatment option in many countries because of practical limitations 
on the use of percutaneous interventions including a shortage of cardiac 
catheter facilities and appropriately skilled staff.  The choice of appropriate 
management also needs to consider the possible time delay in initiating 
reperfusion with primary angioplasty compared to thrombolysis. The effect of 
this angioplasty-related time delay in reducing the mortality benefit of 
angioplasty relative to thrombolysis has been demonstrated using meta-
regression methods.8,9 
 
This work has been influential in clinical guidelines for the management of 
AMI.10,11 For example, European guidelines suggest that primary angioplasty is 
the “preferred treatment if performed by an experienced team less than 90 
minutes after first medical contact”.11  However, there are some limitations in 
the analyses informing these guidelines.  A key meta-analysis only had 
abstracts available for some trials,2 and inaccuracy in data extraction has been 
observed.12  The quantification of the relationship between the benefit of 
angioplasty and time delay until its initiation did not quantify the uncertainty 
around this relationship, and the analysis was restricted to a sub-set of major 
clinical events.8   
 
This paper seeks to build on these previous analyses by extending their scope 
and statistical rigor.  It assesses how the treatment effect of angioplasty on fatal 
and non-fatal outcomes (re-infarctions and strokes) relates to the additional 
delay involved in initiating angioplasty.  It also considers both the 1-month and 
the 6-month outcome data reported in randomised clinical trials.  Furthermore, 
in using Bayesian statistical methods, the paper is able to quantify more fully 
the uncertainty associated with the estimated relationships.   
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METHODS 
Search strategy and data extraction 
To identify trials comparing intravenous thrombolysis and primary angioplasty in 
patients with STEMI, the analysis used an earlier review2 as a starting point. To 
update this review, the following databases were searched: Cochrane 
Controlled Trials Register, UK National Research Register, Medline, Embase, 
Database of Abstracts of Reviews of Effects, UK National Health Service 
Economic Evaluation Databases, and Health Technology Assessment 
Database.  The searches were restricted to English-language studies published 
between 2002 and 2004. The inclusion criteria were consistent with those used 
previously.2,5  Full details of the search strategy are available in a technical 
report {note to the editor: a technical report is submitted with this paper with a 
view to web-based publication}. 
 
Two researchers (YB, CA) independently extracted the clinical data. Outcomes 
of interest were mortality, non-fatal re-infarctions, fatal and non-fatal strokes, 
and hemorrhagic strokes, as well as any data regarding time delay to treatment 
initiation.  Discrepancies were resolved by consensus, and a third researcher 
(SP) was consulted when necessary.  Data were also extracted on the 
difference between time-to-balloon in angioplasty and time-to-needle in 
thrombolytic therapy.  This definition emphasises the differences in times to 
initiation of treatment between the two reperfusion strategies, thus avoiding the 
problem of different timing definitions across studies.  Mean times to treatment, 
together with their standard deviations, were preferred in the analysis, but 
medians and quartiles were used when these were not available.  Where the 
earlier review2 had used preliminary data from conference abstracts, these were 
updated with final trial reports; the earlier data extraction was also checked and 
any inaccuracies were corrected.    
 
Statistical methods   
The comparison in the meta-analysis was between primary angioplasty and 
thrombolysis (regardless of type of drug).  Because only a limited number of 
trials reported 6-month data on fatal or hemorrhagic strokes, these endpoints 
were excluded from the meta-analysis.  Thus three outcomes (death, non-fatal 
strokes, and non-fatal re-infarctions), for which sufficient data were available, 
were analysed using an intention-to-treat principle. 
 
The analysis was undertaken using Bayesian statistical methods.13-15 These 
methods were used because they are more suitable for synthesising evidence 
when there are differences between trials in, for example, follow-up times and 
reported outcomes.  An important feature of Bayesian methods is that they use 
external evidence (so called ‘prior distributions’) which represent beliefs about 
the evidence and its uncertainty external to the data extracted from the trials.  
This analysis has used ‘non-informative’ prior distributions so that the data are 
dominant in the results presented.  A sensitivity analysis was undertaken to 
verify that changing the specification of the prior distribution did not alter the 
results substantially.  Bayesian methods also enable direct probability 
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statements to be made about quantities of clinical interest, e.g. the probability 
that an intervention is superior to another. 13,14 
 
Full details of the statistical methods are presented in the technical report.  
Briefly, the meta-analysis models all outcomes of interest as probabilities on the 
log-odds scale, and results are reported in terms of the absolute probability of 
specific events and odds ratios (with 95% credible intervals (CrI)).  It is 
assumed that baseline event rates (i.e. clinical events in the thrombolysis arms) 
vary randomly between trials, where the degree of variation is estimated from 
the data (a ‘random effect’ assumption).  That is, although the patient 
populations in different trials are not identical, they are similar to each other.  So 
the results of the analysis are only valid for patient populations similar to a 
hypothetical ‘average’ trial population.   
 
For each outcome measure, the relative treatment effect of primary angioplasty 
compared to thrombolytic treatment is modelled as a ‘random effect’; similar but 
not identical between trials.  This relative treatment effect is estimated as a 
function of the time delay related to the initiation of angioplasty.  This 
relationship is used to establish the extent to which any additional effectiveness 
of angioplasty is affected by the additional time it takes to deliver the 
intervention compared to thrombolysis, whilst taking into account the uncertainty 
surrounding the average delay in each trial.  When interpreting the results of 
such a ‘meta-regression’, caution is needed in extrapolating the relationship 
beyond the data on time delay observed in the trials.  Also, it should be 
recognised that, at the extremes of the time delay data, uncertainty in the 
estimates relationship will be greater than around the mid-point.   
 
A feature of the evidence base is that some trials report outcomes at 1 month 
follow-up, some at 6 months follow-up and some at both.  In order that all these 
data can be used, outcomes at 1 month and 6 months are assumed to differ by 
a random effect.16 This reflects the fact that clinical events are more likely to 
occur within the first month following AMI and, by allowing a relationship 
between outcomes at the two time-points, more of the data can be used in the 
analysis. Thus, those studies which do not report at 6 months can ‘borrow 
strength’ both from those that do and from their own results at 1 month. 
 
RESULTS 
Summary of the trial evidence 
A total of 24 studies met the inclusion criteria.  Two of the studies were 
subsequently excluded from the meta-analysis.  One of these was excluded 
because it did not report times to treatment and, as such, could not provide data 
on the delay to primary angioplasty.17 The SHOCK study18 was also excluded 
because the primary comparison was between emergency revascularization 
without differentiating results by type of intervention (angioplasty 64%, surgery 
36%), and hence this treatment strategy is not directly comparable with primary 
angioplasty in the other trials.  
 
Table 1 lists the remaining 22 studies included.  In comparison with the earlier 
review,2 one additional trial19 was identified which had not been published at the 
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time. In addition, full trial results were available for three studies that had 
previously been reported in abstract form only.20-22  
 
Table 1 lists the data extracted from the 22 trials.  In total, these trials included 
3,760 and 3,758 patients randomised to primary angioplasty and thrombolysis, 
respectively.  Eight of the 22 trials used streptokinase as the form of 
thrombolysis, and 14 used t-PA.  For angioplasty, 13/22 trials used coronary 
stents, and 8 studies used glycoprotein IIb/IIIa antagonists.  The mean value of 
angioplasty-related time delay (over and above time to thrombolysis) was 54.3 
minutes (S.E. 2.2).  All trials reported outcomes at between 30 days and 6 
weeks (both are referred to as ‘1 month’ in the meta-analysis results) after the 
initial MI; 10 out of the 22 trials also reported outcomes at 6 months follow-up.  
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Table 1. Overview of trials and key endpoints and time to treatment for primary angioplasty (A) and thrombolysis (T).   
 
1 month (4-6 weeks) 6 months Time  (minutes) 
N Death NF Reinfarction NF Stroke N Death NF Reinfarction NF Stroke 
Mea
n 
Mea
n 
 
 
 
Study  (A) (T) N (A)/(T
) 
O.R. 
(95% 
CrI) 
N 
(A)/(T
) 
O.R. 
(95% 
CrI) 
N 
(A)/(T
) 
O.R. 
(95% 
CrI) 
(A) (T) N  
(A)/(T
) 
O.R. 
(95% 
CrI) 
N  
(A)/(T
) 
O.R. 
(95% 
CrI) 
N  
(A)/(T
) 
O.R. 
(95% 
CrI) 
(A) (A) 
Zijlstra et 
al 199323§ 70 72 0 / 4 
0.1 
(0 – 
7.7) 
0 /9 
0.1 
(0.0 – 
4.8) 
0 / 2 
0.2 
(0.0 – 
12.4) 
- - - - - - - - 61 30 
Ribeiro et 
al 199324§ 50 50 3 / 1 
3.1 
(0.2 – 
16) 
4 / 5 
0.7 
(0.2 – 
3.5) 
- - - - - - - - - - 238 179 
Zwolle  
1994§19 
15
2 
14
9 3 / 11 
0.3 
(0.2 – 
2) 
2 / 15 
0.1 
(0.0 – 
1.7) 
1 / 2 
0.4 
(0.0 – 
8.1) 
- - - - - - - - 195 176 
Berrocal et 
al
 200320§ 54 58 5 / 6 
0.9 
(0.3 – 
3.3) 
1 / 2 
0.5 
(0.0 – 
8.6) 
- - - - - - - - - - 82 15 
Zijlstra et 
al 199725§ 45 50 1 / 0 
2.3 
(0 – 
43) 
0 / 8 
0.0 
(0.0 – 
5.2) 
1 / 2 
0.5 
(0.0 – 
8.7) 
45 50 1 / 0 
2.2 
(0.0 – 
43.4) 
0 / 8 
0.0 
(0.0 – 
5.2) 
1 / 2 
0.5 
(0.0 – 
8.7) 
68 29 
Widimsky 
et al 
200026§ 
10
1 99 7 / 14 
0.5 
(0.3 – 
1.8) 
1 / 10 
0.0 
(0.0 – 
2.7) 
0 / 0 
1 
(0.0 – 
50.4) 
- - - - - - - - 96 90 
de Boer et 
al 200227§ 46 41 3 / 8 
0.3 
(0.1 – 
2.4) 
1 / 6 
0.1 
(0.0 – 
3.5) 
1 / 2 
0.4 
(0.0 – 
7.9) 
- - - - - - - - 59 31 
Widimsky 
et al 
21§†
42
9 
42
1 
29 / 
42 
0.7 
(0.5 – 6 / 13 
0.4 
(0.2 – 1 / 9 
0.1 
(0.0 – - - - - - - - - 97 12 
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200321§† 1.4) 1.8) 3.0) 
DeWood et 
al 199028 46 44 3 / 2 
1.5 
(0.2 – 
7.4) 
- - - - - - - - - - - - 126 84 
Grines et 
al 199329 
19
5 
20
0 5 / 13 
0.4 
(0.2 – 
1.9) 
5 / 13 
0.3 
(0.2 – 
1.8) 
0 / 3 
0.1 
(0.0 – 
9.2) 
18
8 
19
0 7 / 15 
0.4 
(0.2 – 
1.7) 
- - - - 60 32 
Gibbons et 
al 199330 47 56 2 / 2 
1.2 
(0.1 – 
8) 
- - - - 47 56 3 / 2 
1.8 
(0.2 – 
8.1) 
0 / 2 
0.2 
(0.0 – 
13.2) 
- - 277 232 
Ribichini et 
al 199831 55 55 1 / 3 
0.3 
(0.1 – 
6.1) 
1 / 2 
0.4 
(0.0 – 
8.3) 
0 / 0 
1 
(0.0 – 
51.31) 
55 55 1 / 4 
0.2 
(0.0 – 
4.9) 
2 / 2 
1 
(0.1 – 
7.3) 
- - 53.2 36.5 
Garcia  et 
al
 199932 
10
9 
11
1 3 / 12 
0.2 
(0.1 – 
1.9) 
4 / 6 
0.6 
(0.2 – 
3.0) 
0 / 2 
0.2 
(0.0 – 
12.3) 
99 91 5 / 13 
0.3 
(0.2 – 
1.7) 
6 / 8 
0.6 
(0.2 – 
2.5) 
- - 197 150 
GUSTO IIb 
199733 
56
5 
57
3 
32 / 
40 
0.8 
(0.6 – 
1.5) 
25 / 
37 
0.6 
(0.4 – 
1.4) 
1 / 5 
0.2 
(0.0 – 
4.2) 
56
5 
57
3 - - - - - - 228 180 
Le May et 
al 200134 62 61 3 / 2 
1.5 
(0.2 – 
7.4) 
3 / 5 
0.5 
(0.1 – 
3.4) 
1 / 1 
1 
(0.0 – 
16.2) 
62 61 3 / 2 
1.5 
(0.1 – 
7.3) 
4 / 10 
0.3 
(0.1 – 
2.1) 
1 / 3 
0.3 
(0.0 – 
6.0) 
77 15 
Bonnefoy 
et al 
200235 
42
1 
41
9 
20 / 
16 
1.3 
(0.6 – 
2.2) 
7 / 15 
0.4 
(0.2 – 
1.7) 
0 / 4 
0.1 
(0.0 – 
7.6) 
- - - - - - - - 190 130 
Schomig et 
al 200036 71 69 3 / 5 
0.6 
(0.2 – 
3.4) 
2 / 4 
0.4 
(0.1 – 
4.0) 
- - 71 69 3 / 9 
0.2 
(0.1 – 
2.2) 
- - - - 65 30 
Vermeer  
et al 
199937† 
75 75 5 / 5 
1 
(0.3 – 
036) 
1 / 7 
0.1 
(0.0 – 
3.4) 
2 / 1 
2 
(0.1 – 
15.3) 
- - - - - - - - 85 10 
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Kastrati et 
al 200238 81 81 2 / 5 
0.4 
(0.1 – 
3.5) 
0 / 4 
0.1 
(0.0 – 
7.6) 
1 / 1 
1 
(0.0 – 
16.2) 
70 71 5 / 7 
0.7 
(0.2 – 
2.8) 
- - - - 75 35 
Aversano 
et al 
200239 
22
5 
22
6 
12 / 
16 
0.7 
(0.4 – 
1.9) 
11 / 
20 
0.5 
(0.3 – 
1.6) 
3 / 8 
0.3 
(0.1 – 
2.4) 
22
5 
22
6 
14 / 
16 
0.8 
(0.4 – 
1.9) 
12 / 
24 
0.4 
(0.3 – 
1.4) 
5 / 9 
0.5 
(0.2 – 
2.3) 
101.
5 46 
Grines et 
al 200240 71 66 6 / 8 
0.7 
(0.3 – 
2.6) 
1 / 0 
1.8 
(0 – 
39.7) 
0 / 3 
0.1 
(0.0 – 
8.9) 
- - - - - - - - 174 63 
Andersen 
et al 2003: 
Referral22* 
56
7 
56
2 
37 / 
48 
0.7 
(0.6 – 
1.4) 
11 / 
35 
0.2 
(0.2 – 
1.1) 
9 / 11 
0.8 
(0.3 – 
2.2) 
- - - - - - - - 90 20 
Andersen 
et al 2003: 
Invasive22* 
22
3 
22
0 
15 / 
13 
1.1 
(0.5 – 
2.3) 
2 / 14 
0.1 
(0.0 – 
1.8) 
0 / 5 
0.0 
(0.0 – 
6.6) 
- - - - - - - - 63 20 
 
Reinf. = reinfarction; SD = standard deviation; CrI = credibility interval 
 
*  This trial consisted of two sub-trials, labelled ‘Referral’ and ‘Invasive’, and these are analysed as if they are two separate studies. 
† Includes a third group of patients who received thrombolytic therapy followed by transfer to angioplasty; these third comparators 
were excluded from the present analysis. § Trial used streptokinase as part the thrombolytic arm, all other trials used t-PA. 
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Meta-analysis 
Table 2 shows the estimated probability of each outcome occurring within 1 month or 
6 months after initial treatment with primary angioplasty or thrombolytics.  These 
results are based on the average angioplasty-related time delay of 54.3 minutes 
reported in the trials, estimated as a weighted average, the weights being the total 
number of patients in each trial. For all outcomes, the mean probability of an event 
occurring is lower for patients randomised to primary angioplasty.  In particular, 
mortality within 1 month is estimated to be 4.5% following angioplasty and 6.4% after 
thrombolysis, with an odds ratio of 0.68 (95% CrI 0.46, 1.01).   For non-fatal re-
infarction, the odds ratio is 0.32 (95% CrI 0.20, 0.51); and for non-fatal stroke it is 
0.24 (95% CrI 0.11, 0.50).  Table 2 also shows estimated results for the 6-month 
endpoints which are very similar to those at 1 month, indicating that the majority of 
events happen in the first month after randomisation. 
 
As the additional time delay to initiation of primary angioplasty is modelled explicitly, 
it is possible to predict how particular angioplasty-related time delays influence the 
clinical superiority of angioplasty.  For angioplasty delays of 30, 60 or 90 minutes, the 
absolute probability differences and the odds-ratios of angioplasty versus 
thrombolytic therapy are shown in Table 3.  If angioplasty could be initiated within 30 
minutes of possible thrombolysis, the absolute probabilities of mortality, non-fatal re-
infarction and non-fatal stroke at 6 months would be, respectively, 3.7%, 4.6% and 
1.7% lower than those with thrombolysis.  For any of these outcomes, the benefit of 
angioplasty decreases with longer delay until its initiation.  
 
This effect is shown in more detail in Figure 1.  In terms of mortality, angioplasty is 
superior to thrombolysis, on average, at time delays up to 90 minutes.  Moreover, in 
terms of the 1-month outcome of mortality, the probability that it is superior is 97%, 
for an additional delay of up to around 60 minutes.  For the 6-month outcome of 
mortality, there is over 95% probability that angioplasty is superior for delays of up to 
around 45 minutes and 87% for delays up to around 60 minutes. However, this 
probability goes below 50% for delays at 90 minutes and beyond, where thrombolysis 
could therefore be the preferred option at least for the 6-month mortality outcome.  
For non-fatal re-infarction and non-fatal stroke, primary angioplasty is superior, on 
average, even if it requires an additional time of up to 2 hours to achieve reperfusion 
with that method.  For both non-fatal outcomes at one month, there was over 95% 
probability that angioplasty is superior at additional delays of up to 90 minutes.  For 
the corresponding 6-month outcomes, there was over 95% probability that 
angioplasty was superior at delays up to 80 minutes.   
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Table 2.  Estimated absolute probabilities of the occurrence of various 
endpoints 1 month or 6 months after angioplasty or thrombolytic therapy 
(mean and 95% CrI), together with the odds ratios (95% CrI) comparing primary 
angioplasty and thrombolysis and probabilities that angioplasty is superior.  
The results are for the average observed ‘angioplasty-related time delay’ (i.e. 
54.3 minutes).   
 
1-month 
endpoints 
Probability 
(angioplasty) 
Probability 
(thrombolytics) Odds 
ratio 
Probability 
angioplasty 
superior  
Death 4.5% 
(3.0%, 6.5%) 
6.5%  
(4.5%, 9.0%) 
0.68 
(0.46, 
1.01) 
0.97 
Non-fatal 
reinfarction 
2.0% 
(1.2%, 3.1%) 
6.1% 
(4.1%, 8.5%) 
0.33 
(0.20, 
0.51) 
1.00 
Non-fatal 
stroke 
0.5% 
(0.2%, 0.9%) 
1.9% 
(1.0%, 3.2%) 
0.26 
(0.11, 
0.50) 
1.00 
     
6-month 
endpoints 
Probability 
(angioplasty) 
Probability 
(thrombolytics) 
Odds 
ratio 
Probability 
angioplasty 
superior 
Death 5.5% 
(3.4%, 8.8%) 
7.7% 
(5.0%, 11.8%) 
0.70 
(0.42, 
1.18) 
0.93 
Non-fatal 
reinfarction 
2.6% 
(1.4%, 4.8%) 
6.9% 
(4.4%, 10.7%) 
0.33 
(0.20, 
0.67) 
0.99 
Non-fatal 
strokes 
0.8% 
(0.2%, 1.0%) 
2.8% 
(1.1%, 6.9%) 
0.26 
(0.08, 
0.72) 
0.99 
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Table 3. Absolute probability differences (thrombolysis minus angioplasty), odds ratios for the 6-month treatment effects 
of angioplasty compared to thrombolytic therapy (mean and 95% CrI) and probability that angioplasty is superior at 
assumed ‘angioplasty-related time delays’ of 30, 60 and 90 minutes.   
 
 Primary angioplasty-related time delay 
 30 minutes 60 minutes 90 minutes 
Endpoint Probability 
difference 
(95% CrI) 
Odds 
ratio 
Probability 
angioplast
y is a 
superior 
treatment  
Probability 
difference 
(95% CrI) 
Odds 
ratio 
Probability 
angioplasty 
is a 
superior 
treatment  
Probability 
difference  
(95% CrI) 
Odds ratio Probability 
angioplasty 
is a 
superior 
treatment  
Death 
–3.5% 
(–7.2%, –
0.5%) 
0.54 
(0.29, 
0.92) 
0.98 –1.8% 
(–5.6%, 
+1.7%) 
0.77 
(0.44, 
1.29) 
0.87 +0.7% 
(–4.6%, 
+8.1%) 
1.15 
(0.49, 
2.36) 
0.44 
Non-fatal 
re-
infarction 
–4.8% 
(–8.2%, –
2.2%) 
0.30 
(0.14, 
0.59) 
0.99 –4.2% 
(–7.5%, –
1.6%) 
0.39 
(0.21, 
0.72) 
0.97 –3.1% 
(–7.1%, 
+1.6%) 
0.55 
(0.2,9 
1.27) 
0.93 
Non-fatal 
stroke 
–2.1% 
(–5.8%, –
0.5%) 
0.47 
(0.05, 
0.69) 
0.99 –2.0% 
(–5.6%, –
0.4%) 
0.56 
(0.09, 
0.75) 
0.98 –1.6% 
(–5.3%, 
+0.8%) 
0.79 
(0.08, 
1.43) 
0.93 
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Figure 1. Treatment effect of primary angioplasty relative to thrombolytic 
therapy, in terms of the absolute probability differences for each key outcome 
(death, non-fatal re-infarctions, non-fatal strokes) and point of follow-up (1-
month, 6-month).  The graphs show means and 95% CrIs plotted against the 
additional time delay to initiating primary angioplasty. Values above the x-axis 
indicate that angioplasty results in fewer clinical events.  Each point 
represents a trial and their size is proportional to the trial sample size.  
 
 
DISCUSSION 
The contribution of this review is twofold.  Firstly, it updates the most 
comprehensive recent meta-analysis of randomised trials comparing primary 
angioplasty and thrombolysis in patients with STEMI.2 Secondly, it extends 
the evidence synthesis by evaluating the relationship between the treatment 
effects of angioplasty and time delay, expressed as the difference in times to 
initiation of treatment between the two reperfusion strategies. Furthermore, to 
our knowledge, this is the first study that explicitly models the measurement 
uncertainty associated with angioplasty-related time delay. 
 
Although Keeley et al2 do not directly address the issue of time delay, the 
main results in that study can be compared with those presented here for the 
average time delay of 54.3 minutes.  For mortality at 1 month, Keeley et al 
found an odds ratio of 0.70 (95% confidence interval 0.58, 0.85), which is 
similar to that reported here, although our estimate does not reach statistical 
significance.  This lack of statistical significance is likely to be due to 
differences in the data extraction,12 the inclusion of additional evidence, and 
also because the measurement uncertainty in the time delay covariate is 
explicitly considered here.  For the outcome of non-fatal re-infarction, the 
results here are similar to those of Keeley et al, in terms of both the magnitude 
and uncertainty of the odds ratio. The analysis of the stroke outcome is not 
comparable to that in Keeley et al which included all strokes compared to the 
non-fatal strokes considered here. Although a separate analysis of the longer-
term follow-up data was undertaken by Keeley et al, these results were not 
presented in sufficient detail to allow a reliable comparison between the two 
sets of analyses at 6 months. Another reason why there will be slight 
differences between the two meta-analyses is that in ours the uncertainty in 
the between-study variability of the effect is appropriately taken in to account 
thus producing slightly wider CrIs than those obtained using Classical meta-
analysis methods.14,15  
 
Based on research undertaken during a similar period to our own, Boersma et 
al.41 have also recently demonstrated, using individual patient data from 22 
trials, that angioplasty is associated with significantly lower 30-day mortality, 
re-infarction and stroke relative to thrombolysis, regardless of delay in 
presentation. The main results in that study for the overall angioplasty-related 
delay of 55 minutes can be compared with those presented here for the 
average time delay of 54.3 at 1-month (Table 2) although there were minor 
differences in the trials included in the two studies.  The absolute differences 
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in the risks of non-fatal MI and stroke between angioplasty and thrombolysis 
at one month were very similar (4.3% vs 4.1% for non-fatal MI and 1.7% vs 
1.4% for non-fatal stroke in Boersma et al and the current study, respectively). 
The estimated absolute reduction in mortality risk with angioplasty at one 
month was higher in the Boersma et al study: 2.6% versus 2%.  As seen in 
previous studies,8,42 the benefit of angioplasty in terms of mortality decreases 
the longer the time delay to initiation of angioplasty.  However, none of these 
studies (including Boersma et al.41) quantify the uncertainty in this relationship 
fully. The comprehensive handling of uncertainty in the current analysis allows 
the precision associated with the relationship to be presented (Figure 1).  The 
Bayesian approach also facilitates the presentation of results in terms of the 
probability of one intervention of being the superior treatment.   
 
This is the first study to link explicitly short-term (1 month) with longer-term (6 
months) outcomes using as much of the available clinical evidence as 
possible.  Although none of the trial data indicate systematic differences 
between the relative treatment effect of primary angioplasty at 1 month and at 
6 months, fewer data are generally available at 6 months resulting in greater 
uncertainty.  It is, therefore, not surprising that the point estimates of the 
relative treatment effect of angioplasty are similar at the two time-points, but 
with greater uncertainty at 6-month endpoints. Thus, a probability of 
superiority of angioplasty in terms of the 6-month mortality endpoint of greater 
than 0.95 can be identified for delays of up to around 45 minutes only, whilst 
for delays at around 90 minutes thrombolysis appears to be superior. 
However, angioplasty appears to be superior for 6-month non-fatal outcomes, 
on average, for delays up to around 90 minutes. It should be noted, however, 
that the uncertainty in these relationships shown here is less than it would 
have been had only 6 month follow-up data been used in the analysis due to 
the paucity of the data. 
 
The analysis suggests, therefore, that angioplasty performs better than 
thrombolytic therapy but this superiority is related to angioplasty-related time 
delay.  It should be emphasised, however, that no trials have been identified 
which show a statistically significant advantage for thrombolysis at very long 
angioplasty-related time delays.  Moreover, the PRAGUE-2 trial indicates that 
angioplasty performs better than thrombolysis even when it involves a patient 
transfer of up to 3 hours.21 Without more evidence at long angioplasty-related 
time delays, the linear regression model estimated here will inevitably indicate 
that the relative treatment effect of primary angioplasty becomes negative at 
an unspecified delay.  This is not because of data showing this effect, but 
simply because a consistent relationship has been observed for a range of 
relatively short time delays. In reality, for delays approaching 2 hours, this 
study can neither confirm nor refute whether angioplasty is better than 
thrombolytic treatment. 
 
This study has some limitations.  Firstly, the lack of individual patient data 
precludes the analysis of how the relative effect of angioplasty varies between 
patient sub-groups, and whilst this analysis has taken account of the 
uncertainty in the average time delay, thus reducing the possibility of 
ecological fallacy,43 the presence of an ecological bias cannot be entirely 
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
 15
eliminated. However, this is less of an issue when it is recognized that the aim 
of this study is to provide evidence to support population-based decisions 
using cost-effectiveness analysis as reported in the companion paper {ref to 
CE paper}.  However, an analysis of individual patient data would also enable 
a more appropriate estimate of the impact or otherwise of time delay on 
outcome to be obtained.44,45 Secondly, time-to-needle is a predictor of the 
success of thrombolytic treatment, but this effect could not be included in the 
analysis explicitly due to inconsistent reporting of the data in the trials.  Hence 
the results are based on the average time-to-needle in the studies considered, 
which, at 75 minutes, was shown to be similar to the median call to needle 
time (67 minutes) in the UK (personal communication, Dr John Birkhead, UK 
Myocardial Infarction National Audit Project).  Further research would be 
desirable to identify all external evidence on the effect of time-to-needle on 
outcomes and incorporate this into our analysis via appropriate prior 
distributions taking account of relevance and quality.15    Thirdly, given this 
review was an update of those published earlier, neither the effect of 
publication bias, study quality or the influence of individual studies were 
formally assessed on the overall meta-analysis results. Fourthly, further 
exploration of whether the potential relationship between time-delay and effect 
(log odds ratio) is linear may be of merit.  
 
The final limitation concerns the use of older streptokinase trials in the meta-
analysis.  Keeley et al were criticised46 for including these trials in their meta-
analysis because, by effectively averaging across the thrombolytic trials, the 
additional benefit of angioplasty may have been over-estimated.  However, 
streptokinase is the most common form of thrombolytic therapy used in many 
countries and is used in about a third of patients in the UK (personal 
communication, Dr John Birkhead, UK Myocardial Infarction National Audit 
Project).  In the present meta-analysis, the differences between thrombolytic 
drugs were ignored with a focus on primary angioplasty or thrombolysis as 
two treatment groups. If only t-PA trials were analysed, the relative benefit of 
primary angioplasty is attenuated: 1-month odds-ratios for mortality are found 
to be 0.71 (95% CrI 0.44, 1.16); for non-fatal re-infarction, 0.41 (95% CrI 0.23, 
0.71); and for non-fatal strokes, 0.23 (95% CrI 0.08, 0.57). Full details of this 
sensitivity analysis are reported in the technical report. 
 
The policy implications of this analysis should be seen in the context of the 
relevant health care system. For example, US guidelines currently 
recommend that primary angioplasty should be used only within an 
angioplasty-related delay of less than 60 minutes.10 The guidelines, however, 
seem to be based largely on the work of Nallamothu and Bates,8 and may be 
premature because angioplasty appears to convey health benefits even when 
the delay is longer than 60 minutes.  Even at delays longer than 1 hour, 
angioplasty is superior, on average, for all the 1-month outcomes included in 
this study, although there is considerable uncertainty associated with these 
estimates. 
 
What size of treatment effect would be necessary with primary angioplasty to 
be considered worthwhile given the major changes in service organization 
necessary for its implementation? This issue is considered directly in the cost-
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effectiveness analysis submitted as a companion paper, which addresses 
whether the health benefits of primary angioplasty are sufficient to justify its 
additional cost.  With respect to the absolute size of treatment effect with 
primary angioplasty, our analysis shows that the probability that primary 
angioplasty reaches at least a 1%, 2% and 3% improvement in survival at 1-
month relative to thrombolysis is 0.82, 0.47 and 0.15, respectively, at the 
average angioplasty-related time delay.  In short, the benefit of timely 
treatment is the key: If primary angioplasty can be delivered in a timely 
fashion, current evidence supports its use; if not, the choice of treatment 
probably depends on time from onset of symptoms to presentation21, 41 and 
the availability of pre-hospital thombolysis.35  
 
Decisions about appropriate methods of reperfusion should consider not only 
the effectiveness of each treatment option, but also their cost-effectiveness. 
With the quantification of both the expected treatment effects of angioplasty, 
with regard to several possible outcomes, and the uncertainties associated 
with these predictions, this meta-analysis using Bayesian methods lays the 
foundations for a robust cost-effectiveness analysis, in which other treatment 
strategies may be considered, and in which appropriate account is taken of 
statistical, clinical and methodological heterogeneity and all sources of 
uncertainty.47 
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Technical Appendix  [Note to editor: this appendix could be web-based 
or published with the paper.] 
The results of the 22 trials identified were formally combined using meta-
analytic approaches. A Bayesian evidence synthesis is implemented48 using 
specialist software (WinBUGS).49 A random-baseline, random-effects 
approach is adopted for each outcome measure50,51 that incorporates a linear 
regression of the treatment effect (log odds ratio) on the covariate “PCI-
related time delay”.52  The model assumptions are described step by step 
below. 
 
Multiple outcomes 
In the trial search strategy we identified three clinical outcomes that are 
reported by a sufficient number of trials to inform an evidence synthesis: 
death, non-fatal strokes, and non-fatal re-infarctions. With such binomial 
outcomes, where an event either happens or does not happen, treatment 
effects can be modelled as absolute or relative risk differences or as log-
odds.53  For numerical convenience, we model all treatment effects on the log-
odds scale. To reflect slight differences in recruitment criteria and patient mix, 
for each outcome the baseline event rates are assumed to vary randomly 
around a common mean. 
 
Multiple time-points 
While all trials report outcomes at the 1-month endpoint, a number of trials 
also report clinical events at the 6-month endpoint. However, any event that 
has occurred by 1 month will still have occurred by 6 months, so these 
endpoints are clearly related. Statistically, such a situation can be modelled by 
assuming that, for each treatment arm and outcome, the 1-month and the 6-
month endpoints differ by a random effect, additive on the log-odds scale. We 
assume that these random effects are unrelated to the covariates that may 
explain some of the variation in the treatment effect of PCI compared to 
thrombolytic therapy.  
 
Treatment effect of PCI relative to thrombolysis  
For each trial and outcome, we model the treatment effect of PCI relative to 
thrombolysis as a random effect additive on the log-odds scale, respecting 
both the randomisation in the clinical trial and the heterogeneity of treatment 
effects measured by different trials. We assume that the same mean 
treatment effect of PCI, relative to thrombolysis, applies at both the 1-month 
and the 6-month time-point of each trial.  This assumption is supported in the 
trial reports, which show that most clinical events occur within a few days from 
the initial episode (e.g. Aversano et al39, Schomig et al54, Le May et al34, 
García et al32). We do not attempt to impute the 6-month data for those trials 
that did not report it and, therefore, the average treatment effect of PCI 
relative to thrombolytic therapy will be informed more strongly by the 1-month 
data that are reported more commonly.  The mean treatment effect of PCI, 
relative to thrombolysis, is modelled in terms of the covariate “PCI-related time 
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delay” (i.e. the additional time to PCI over and above thrombolysis) by linear 
regression [e. g. Berkey et al 199852].  
Correlated outcomes 
We identify and model two sources of correlation between event rates.  
Baseline log-odds for the three outcomes are correlated across trials (e. g. 
high baseline mortalities may systematically coincide with elevated or reduced 
rates of non-fatal strokes). Also, within each outcome, we model correlation of 
the four endpoints (1-month and 6-month endpoints on two treatment arms), 
but we allow the exact nature of these correlations to vary dependent on 
outcome [e. g. van Houwelingen et al 200251].  We parameterise all the above 
correlations by multivariate normal distributions (on the log-odds scale).  
Covariate “PCI-related time delay” 
To model the measurement error in the covariate “PCI-related time delay”, we 
model independently the delays associated with each treatment (time to 
needle/balloon) as measured in each trial, and calculate the value of the 
covariate by subtraction. For each treatment arm, the trial reports give a 
summary statistic (i.e. mean with standard error, or median with confidence 
interval), which we have interpreted to obtain a prior mean and variance under 
the assumption of normality. For those trials that do not report the variability in 
times to treatment,26,28,37 we used the corresponding average values from the 
other trials. Because treatment effect in our model only depends on the “PCI-
related time delay”, i.e. the difference between the delays in the two arms of 
each trial, it is irrelevant whether a trial measures the time from occurrence of 
symptoms to reperfusion, or from randomisation to beginning of treatment as 
long as both arms of the trial are consistent, and assuming that there is no 
within-trial correlation.  
 
Statistical Model 
Table A1 shows the equations used in the analysis for each component of the 
model. Throughout, let j  index the trials and i  index the clinical endpoints. 
Also, let capital letters N , R  stand for the 6-month endpoint data, and small 
letters n , r  denote 1-month endpoint data from the trials, for the two arms 
TPx ,=  (PCI or thrombolytics). Probabilities π  are estimated on the log-odds 
scale. Baseline probability log-odds are denoted by µ . Random effects are 
modelled as additive on the log-odds scale, and the mean underlying 
probabilities shall be denoted by λ . The log-odds differences between 1-
month and 6-month probabilities are denoted by ω . Time delays, as 
measured in each trial arm, shall be written as δ , their means as δ , and the 
observed variance as v . The covariate “PCI-related time delay” is denoted by 
∂ , and the coefficients of the linear regression by α  (intercept) and β  
(slope). 
 
Wishart prior distributions were used for the covariance matrices, in which the 
degrees of freedom were set to the rank of the covariance matrix, whilst for 
means and regression parameters Normal or half-Normal prior distributions 
were assumed in which hyper-prior uniform distributions for the corresponding 
standard deviation were used.  
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Parameter Estimation 
The parameters of the model were estimated using Markov Chain Monte 
Carlo (MCMC) methods as implemented in WinBUGS software 1.4.1.49 
Convergence was assessed via sensitivity analyses with respect to initial 
values, length of ‘burn-in’ and length of sample, using both visual inspection of 
trace plots, and by running multiple chains assessed by the Gelman-Rubin 
convergence statistic.55 Final parameter estimates are based on a ‘burn in’ of 
5,000 and a sample of 35,000 iterations. 
 
Sensitivity analyses with respect to prior distributions, especially for the 
covariance matrices were also undertaken. 
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Table A1.  The equations used in the analysis for each component of the 
model 
Model 
component 
Equations (for all i , j , x , where appropriate) 
Trial data ( )xjx jixji nBinr ,~ ,, π  and ( )xjx jix ji NBinR ,~ ,, Π  
Probabilities on 
logit scale x jix
ji
x
ji
,
,
,
1log λπ
π
=








−
 and x jix
ji
x
ji
,
,
,
1log Λ=






Π−
Π
 
Correlated within-
outcome errors 




























Λ
Λ














Λ
Λ i
P
ji
T
ji
P
ji
T
ji
P
ji
T
ji
P
ji
T
ji
XMVN ,~
,
,
,
,
,
,
,
,
λ
λ
λ
λ
  where Xi is the between-time-
point covariance matrix for the ith outcome and is 
assumed constant across trials. 
Explain treatment 
effects 
x
i
x
ji
x
ji ωλ +=Λ ,,  to relate 1-month and 6-month outcomes, 
jii
T
ji
P
ji ∂⋅++= βαλλ ,,  for the treatment effect 
Random baselines 






























=
=
=
YMVN
T
ji
T
ji
T
ji
,~
3
2
1
,3
,2
,1
µ
µ
µ
λ
λ
λ
  where Y is the between-
outcome covariance matrix for thrombolytic therapy and 
is assumed constant across trials. 
time delay 
covariate 
T
j
P
jj δδ −=∂  
Measurement error 
in time delay 
( )xjxjxj vN ,~ δδ  
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